[Edaily Reporter NA EUN-KYUNG ] Humedix Co., Ltd.(200670)and Huons Co., Ltd. announced on the 20th that they held a launch symposium for the botulinum toxin “HuTox” on the 16th at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China.
The “Hyutox Launch Symposium” was held on the 16th at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. The photo shows Dr. Kim Geon-woo, Director of Cheongdam Cellinic Clinic, delivering a presentation. (Photo courtesy of Huons Co., Ltd.)
Organized by Huons Co., Ltd.’s Chinese partner, IMeik Technology, the symposium featured product presentations and academic sessions for local medical professionals and industry representatives to commemorate the launch of HuTox in China.
Dr. Kim Geon-woo, Director of Cheongdam Cellinic Clinic, attended the event as a speaker and presented on global trends in botulinum toxin treatments, clinical application cases of HuTox, and his practical treatment experience.
Humedix Co., Ltd. and Huons Co., Ltd. explained that through this symposium, they focused on expanding their engagement with Chinese medical professionals and sharing clinical experience and use cases for HuTox. Humedix Co., Ltd. supported the invitation of speakers and the operation of the academic program by leveraging its network of domestic medical professionals.
Hutox is a botulinum toxin product used to improve glabellar lines and crow’s feet.
In 2022, iMaker signed an exclusive import and distribution agreement for HuTox in China (including Hong Kong and Macau) with Huons Co., Ltd., and in January of this year, it obtained product approval from the China National Medical Products Administration (NMPA).
#A Huons Global Co., Ltd. official stated, “This launch symposium served as an opportunity to introduce Huotox’s clinical experience and global use cases to Chinese medical professionals and industry stakeholders,” adding, “We will continue to strengthen the brand’s competitiveness in the Chinese market through various academic activities and marketing efforts.”
SK Eco Plant and KCC Corporation(002380)achieved a successful public offering of corporate bonds, drawing a favorable response in the bookbuilding process despite significant uncertainty caused by a s…
As medical technology advances, the treatment of human diseases is evolving toward “personalized” and “precision medicine.” Consequently, demand for personalized treatment and precision medicine is no…
On July 23, the domestic stock market surged as expectations for artificial intelligence (AI) investments combined with strong momentum in healthcare and biotechnology stocks. The tech-heavy KOSDAQ ma…
